Trial Profile

A Phase 4, Multicenter, Single-Arm, Open-Label Study to Evaluate the Impact of Apremilast (CC-10004) on MRI Outcomes in Subjects With Active Psoriatic Arthritis

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 10 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apremilast (Primary) ; Glucocorticoids; Methotrexate; Nonsteroidal anti-inflammatories; Prednisone
Indications Psoriatic arthritis
Focus Therapeutic Use
Acronyms MOSAIC
Sponsors Amgen; Celgene Corporation

04 Feb 2025 According to an Amgen media release, in November 2024 data from this study was presented at the American College of Rheumatology (ACR).
15 Jun 2024 Results assessing efficacy of apremilast in Patients with Psoriatic Arthritis presented at the 25th Annual Congress of the European League Against Rheumatism
15 Jun 2024 Results(n=122) evaluating the efficacy of apremilast on axial inflammation in PsA , presented at the 25th Annual Congress of the European League Against Rheumatism

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com